Clinical Trial Update: Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study of SAR445088 for chronic inflammatory demyelinating polyneuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• SAR445088

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 | Status: COMPLETED